Cardio Diagnostics Holdings Inc
Follow $CDIO
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $CDIO by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is CDIO moving today?
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
CDIO overview
Related filings and maps
Congress activity in CDIO
No receipt-qualified Congressional disclosure is present for CDIO in the cached public ledger.
CDIO contract awards, year to date.
Public federal awards linked to this ticker.
CDIO lobbying filings, year to date.
Registered lobbying filings matched to Cardio Diagnostics Holdings Inc.